Patents by Inventor James A. Garegnani
James A. Garegnani has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20160271120Abstract: A pharmaceutical composition for cleansing the gastrointestinal tract prior to a colonoscopy or other gastrointestinal procedure is provided. The composition comprises polyethylene glycol and sodium picosulfate and is suitable to make up to 1.5 liters of aqueous solution for oral administration.Type: ApplicationFiled: February 24, 2016Publication date: September 22, 2016Applicant: Oakdene Holdings LLCInventors: Aman Trehan, James Garegnani
-
Publication number: 20160263102Abstract: A pharmaceutical composition of bupropion or salts thereof and naltrexone or salts thereof is provided. The composition comprises bupropion and naltrexone in a single matrix core. The two active ingredients are not physically separated and neither represents a separate layer. A method of manufacturing the composition is also provided.Type: ApplicationFiled: February 1, 2015Publication date: September 15, 2016Applicant: GAVIS PHARMACEUTICALSInventors: James Garegnani, Velayutham Kanniyappan
-
Publication number: 20160263152Abstract: The present invention provides compositions and methods for facilitating cleansing of the gastrointestinal tract of a patient prior to a diagnostic, surgical or therapeutic procedure. The composition can improve patient compliance, and thus, efficacy of the preparation. Specifically, the composition of the invention is palatable for the patient to consume. For example, for a patient preparing to undergo colonoscopy, the present methods make the bowel preparation liquid taste significantly less salty.Type: ApplicationFiled: February 29, 2016Publication date: September 15, 2016Applicant: Gavis PharmaceuticalsInventors: Aman Trehan, James Garegnani
-
Publication number: 20160243064Abstract: Oral pharmaceutical compositions of treprostinil, a prodrug, or a pharmaceutically acceptable salt thereof are provided. The compositions possess absolute oral bioavailability of greater than 10% and achieve circulating concentrations when administered orally. Methods of treating prostacyclin responsive conditions including pulmonary arterial hypertension (PAH) by administering such compositions also are provided.Type: ApplicationFiled: February 22, 2016Publication date: August 25, 2016Applicant: Gavis PharmaceuticalsInventors: Aman Trehan, James Garegnani
-
Publication number: 20160243144Abstract: A fixed dose combination formulation of rifaximin or a pharmaceutically acceptable salt thereof and lactulose is provided. The formulation is used for the prevention, treatment, or maintaining remission of HE; reducing the recurrence of HE episodes; reducing the recurrence of HE episodes in a patient refractory or non-responsive to rifaximin or lactulose monotherapy; or reducing the frequency of hospital visit.Type: ApplicationFiled: February 22, 2016Publication date: August 25, 2016Applicant: Oakdene Holdings LLCInventors: James Garegnani, Aman Trehan
-
Publication number: 20160220562Abstract: A pharmaceutical composition of bupropion or salts thereof and naltrexone or salts thereof is provided. The composition comprises individual layers of bupropion or a pharmaceutically acceptable salt thereof and naltrexone or a pharmaceutically acceptable salt thereof in direct contact with each other and without being separated by any intermediate layer. A method of manufacturing the composition is also provided.Type: ApplicationFiled: February 1, 2015Publication date: August 4, 2016Applicant: GAVIS PHARMACEUTICALSInventors: James Garegnani, Velayutham Kanniyappan
-
Publication number: 20160220544Abstract: A pharmaceutical composition comprising granules which comprises sodium picosulfate, citric acid and magnesium oxide, prepared without using any solvent is provided. The composition ensures homogeneity or content uniformity of the ingredients as well as being prepared by a simple manufacturing process. Preferably, the granules in the composition are prepared by compacting and milling a mixture of sodium picosulfate, citric acid and magnesium oxide followed by mixing with other optional ingredients.Type: ApplicationFiled: January 31, 2015Publication date: August 4, 2016Applicant: Gavis PharmaceuticalsInventors: Ganesh Kumar Palaniappan Appavu, Arjun Yadhav Muthukkaruppan, James Garegnani
-
Publication number: 20160220561Abstract: A pharmaceutical composition of bupropion or salts thereof and naltrexone or salts thereof is provided. The composition comprises individual layers of bupropion or a pharmaceutically acceptable salt thereof and naltrexone or a pharmaceutically acceptable salt thereof separated by an intermediate layer. The intermediate layer is devoid of sugar. A method of manufacturing the composition is also provided.Type: ApplicationFiled: February 1, 2015Publication date: August 4, 2016Applicant: GAVIS PHARMACEUTICALSInventors: James Garegnani, Velayutham Kanniyappan
-
Publication number: 20160220492Abstract: A pharmaceutical composition comprising granules of sodium picosulfate, citric acid, magnesium oxide and sodium bicarbonate is provided. The composition has fewer or none of the side effects of those side effects associated with known sodium picosulfate purgatives. The composition also ensures homogeneity or content uniformity of the ingredients and is prepared by a simple manufacturing process.Type: ApplicationFiled: January 31, 2015Publication date: August 4, 2016Applicant: GAVIS PHARMACEUTICALSInventors: Ganesh Kumar Palaniappan Appavu, Arjun Yadhav Muthukkaruppan, James Garegnani
-
Publication number: 20160175257Abstract: A solid oral dosage form of methylphenidate or salts thereof which provide a rapid initial onset of action and a prolonged duration of effect is provided. The solid oral dosage form comprises a matrix core containing methylphenidate or salts thereof coated by a modified release coating and an outer methylphenidate immediate release coating.Type: ApplicationFiled: December 19, 2014Publication date: June 23, 2016Applicant: GAVIS PHARMACEUTICALSInventors: Prabagaran Chandrasekaran, James Garegnani
-
Publication number: 20160166702Abstract: An extended release aqueous suspension composition of methylphenidate or salts thereof is provided. The extended release aqueous suspension of methylphenidate or salts has pH of more than 5.0 and exhibits excellent storage stability when tested for impurity and potency of methylphenidate. The suspension also comprises immediate release and sustained release components of methylphenidate or salts thereof. Following administration of a single dose of the extended release aqueous suspension of methylphenidate, a therapeutically effective amount of methylphenidate is reached in less than an hour, provides a release profile of at least 12 hours and has an in vivo release characterized by one single main plasma concentration peak.Type: ApplicationFiled: December 15, 2014Publication date: June 16, 2016Applicant: GAVIS PHARMACEUTICALSInventors: Prabagaran Chandrasekaran, James Garegnani
-
Publication number: 20160158212Abstract: An extended release aqueous suspension composition of methylphenidate or salts thereof, is provided. The extended release aqueous suspension of methylphenidate or salts has pH below 3.5 and exhibit excellent storage stability when tested for impurity and potency of methylphenidate. The suspension also comprises immediate release and sustained release components of methylphenidate or salts thereof. Following administration of a single dose of the extended release aqueous suspension of methylphenidate, a therapeutically effective amount of methylphenidate is reached in less than an hour, provides release profile of at least 12 hours and its vivo release is characterized by one single main plasma concentration peak.Type: ApplicationFiled: December 3, 2014Publication date: June 9, 2016Applicant: GAVIS PHARMACEUTICALSInventors: Prabagaran Chandrasekaran, James Garegnani
-
Patent number: 6793935Abstract: The present invention is directed to a novel flavored extended release composition which forms a non-effervescent suspension when dropped into a liquid, and the methods of using said supplement, thereby minimizing and eliminating gastric discomfort. This flavored extended release composition provides the additional benefits of palatable taste and pleasant appearance.Type: GrantFiled: February 25, 2002Date of Patent: September 21, 2004Assignee: KV Pharmaceutical CompanyInventors: Marc S. Hermelin, George Paradissis, James A. Garegnani
-
Publication number: 20030108605Abstract: The present invention is directed to a novel flavored extended release composition which forms a non-effervescent suspension when dropped into a liquid, and the methods of using said supplement, thereby minimizing and eliminating gastric discomfort. This flavored extended release composition provides the additional benefits of palatable taste and pleasant appearance.Type: ApplicationFiled: December 30, 2002Publication date: June 12, 2003Applicant: KV Pharmaceutical CompanyInventors: Marc S. Hermelin, George Paradissis, James A. Garegnani
-
Publication number: 20020119183Abstract: The present invention is directed to a novel flavored extended release composition which forms a non-effervescent suspension when dropped into a liquid, and the methods of using said supplement, thereby minimizing and eliminating gastric discomfort. This flavored extended release composition provides the additional benefits of palatable taste and pleasant appearance.Type: ApplicationFiled: February 25, 2002Publication date: August 29, 2002Applicant: KV Pharmaceutical Co.Inventors: Marc S. Hermelin, George Paradissis, James A. Garegnani
-
Patent number: 5445829Abstract: An extended release pharmaceutical formulation adapted to approach zero order release of drug over a 12 to at least 24 hour period, comprised of a mixture of 0 to about 50% of an immediate release particle containing a drug, inert substrate and binder, coated with talc and up to 100% of an extended release particle comprising the immediate release particle coated with a dissolution modifying system containing plasticizers and a film forming agent.Type: GrantFiled: June 15, 1992Date of Patent: August 29, 1995Assignee: KV Pharmaceutical CompanyInventors: George N. Paradissis, James A. Garegnani, Roy S. Whaley
-
Patent number: 5296232Abstract: A controlled-release organic nitrate formulation for once-per-day oral administration is provided by spheres having a core which includes an organic nitrate, and a membrane surrounding the core composed of a pharmaceutically acceptable, film forming polymer. The film forming polymer is effective to permit release of the organic nitrate from the spheres, over a daily dosing period, at a rate that achieves a therapeutically effective level of the organic nitrate, while effecting a drug holiday towards a latter portion of the daily dosing period so as not to induce tolerance.Type: GrantFiled: May 13, 1992Date of Patent: March 22, 1994Assignee: KV Pharmaceutical CompanyInventors: George N. Paradissis, James A. Garegnani, Roy S. Whaley
-
Patent number: 5133974Abstract: An extended release pharmaceutical formulation adapted to approach zero order release of drug over a 12 to at least 24 hour period, comprised of a mixture of 0 to aobut 50% of an immediate release particle containing a drug, inert substrate and binder, coated with talc and up to 100% of an extended release particle comprising the immediate release particle coated with a dissolution modifying system containing plasticizers and a film forming agent.Type: GrantFiled: January 24, 1990Date of Patent: July 28, 1992Assignee: KV Pharmaceutical CompanyInventors: George N. Paradissis, James A. Garegnani, Roy S. Whaley
-
Patent number: 5122384Abstract: A controlled-release organic nitrate formulation for once-per-day oral administration is provided by spheres having a core which includes an organic nitrate, and a membrane surrounding the core composed of a pharmaceutically acceptable, film forming polymer. The film forming polymer is effective to permit release of the organic nitrate from the spheres, over a daily dosing period, at a rate that achieves a therapeutically effective level of the organic nitrate, while effecting a drug holiday towards a latter portion of the daily dosing period so as not to induce tolerance.Type: GrantFiled: May 5, 1989Date of Patent: June 16, 1992Assignee: KV Pharmaceutical CompanyInventors: George N. Paradissis, James A. Garegnani, Roy S. Whaley